Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma

Eitemau Tebyg

• Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide and their combination in severe asthma: a post-hoc analysis
  gan: Shrimanker, R, et al.
  Cyhoeddwyd: (2019)
• Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
  gan: Gunsoy, N, et al.
  Cyhoeddwyd: (2017)
• Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
  gan: Howell, I, et al.
  Cyhoeddwyd: (2024)
• Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
  gan: Bel, E, et al.
  Cyhoeddwyd: (2014)
• Mepolizumab treatment in patients with severe eosinophilic asthma.
  gan: Ortega, H, et al.
  Cyhoeddwyd: (2014)